Lulimac Cream contains Luliconazole 1% w/w, a topical antifungal agent belonging to the imidazole class, indicated for the treatment of superficial fungal infections of the skin. Luliconazole exhibits broad-spectrum antifungal activity by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Lulimac Cream is primarily prescribed for dermatophytosis, including tinea corporis, tinea cruris, and tinea pedis, as well as for treating cutaneous candidiasis and pityriasis versicolor caused by Malassezia species. The cream formulation allows for effective penetration into the stratum corneum, ensuring targeted action at the site of infection. Lulimac Cream is typically applied once daily to the affected area and surrounding skin after cleansing and drying, with treatment duration varying depending on the infection type and severity, generally ranging from 2 to 4 weeks. It is well tolerated, with minimal adverse effects such as mild local irritation, burning sensation, or erythema reported infrequently. Contraindications include hypersensitivity to luliconazole or any cream excipients. Lulimac Cream should be used with caution in pregnant or lactating women, and patients are advised to avoid contact with eyes and mucous membranes during application.